Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.
Sutton R, Venn NC, Law T, Boer JM, Trahair TN, Ng A, Den Boer ML, Dissanayake A, Giles JE, Dalzell P, Mayoh C, Barbaric D, Revesz T, Alvaro F, Pieters R, Haber M, Norris MD, Schrappe M, Dalla Pozza L, Marshall GM. Sutton R, et al. Among authors: boer jm. Br J Haematol. 2018 Feb;180(4):550-562. doi: 10.1111/bjh.15056. Epub 2017 Nov 30. Br J Haematol. 2018. PMID: 29194562 Free article.
Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.
Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, Valsecchi MG, de Menezes RX, Pieters R, Stam RW. Stumpel DJ, et al. Among authors: boer jm. Blood. 2009 Dec 24;114(27):5490-8. doi: 10.1182/blood-2009-06-227660. Epub 2009 Oct 23. Blood. 2009. PMID: 19855078 Free article.
Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.
Boer JM, Koenders JE, van der Holt B, Exalto C, Sanders MA, Cornelissen JJ, Valk PJ, den Boer ML, Rijneveld AW. Boer JM, et al. Haematologica. 2015 Jul;100(7):e261-4. doi: 10.3324/haematol.2014.117424. Epub 2015 Mar 13. Haematologica. 2015. PMID: 25769542 Free PMC article. Clinical Trial. No abstract available.
Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.
Boer JM, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, de Groot-Kruseman HA, Kuiper RP, Hoogerbrugge P, Horstmann M, Zaliova M, Palmi C, Trka J, Fronkova E, Emerenciano M, do Socorro Pombo-de-Oliveira M, Mlynarski W, Szczepanski T, Nebral K, Attarbaschi A, Venn N, Sutton R, Schwab CJ, Enshaei A, Vora A, Stanulla M, Schrappe M, Cazzaniga G, Conter V, Zimmermann M, Moorman AV, Pieters R, den Boer ML. Boer JM, et al. Leukemia. 2016 Jan;30(1):32-8. doi: 10.1038/leu.2015.199. Epub 2015 Jul 23. Leukemia. 2016. PMID: 26202931
Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities.
van der Linden MH, Boer JM, Schneider P, Willekes M, Seslija L, De Lorenzo P, Valsecchi MG, Cazzaniga G, Biondi A, den Boer ML, Pieters R, Stam RW. van der Linden MH, et al. Among authors: boer jm. Haematologica. 2016 Mar;101(3):e95-8. doi: 10.3324/haematol.2014.122119. Epub 2015 Dec 17. Haematologica. 2016. PMID: 26681762 Free PMC article. No abstract available.
Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Boer JM, Steeghs EM, Marchante JR, Boeree A, Beaudoin JJ, Beverloo HB, Kuiper RP, Escherich G, van der Velden VH, van der Schoot CE, de Groot-Kruseman HA, Pieters R, den Boer ML. Boer JM, et al. Oncotarget. 2017 Jan 17;8(3):4618-4628. doi: 10.18632/oncotarget.13492. Oncotarget. 2017. PMID: 27894077 Free PMC article.
301 results